MMIT Reality Check on Pain Narcotic Opioid (May 2020)

According to our recent payer coverage analysis for pain narcotic opioid treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for pain narcotic opioid treatments shows that under the pharmacy benefit, about 35% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Many brand name products (Xtampza ER, Oxaydo) continue to enter this market despite the numerous generics. Given assumed parity in efficacy among remaining name-brand products, contracting for position after a generic is common.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

professional-psychologist-doctor-consult-in-psychotherapy-session
September 23

MMIT Reality Check on Schizophrenia (September 2022)

Read More
woman-suffering-from-bad-headache-or-migraine-appointment-with-doctor-in-office-room
September 16

MMIT Reality Check on Acute Migraine (September 2022)

Read More
doctor-with-senior-woman-infusion
September 9

MMIT Reality Check on Breast Cancer HR+/HER2- (September 2022)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today